lanerkitug + pembrolizumab

This is a combination therapy composed of **lanerkitug** and **pembrolizumab**. **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (**PD-1**) receptor, acting as an an immune checkpoint inhibitor that enhances T-cell–mediated anti-tumor activity by blocking the interaction between PD-1 and its ligands. It is developed and primarily manufactured by Merck and is approved for a broad range of malignancies. **Lanerkitug** is not found in the referenced regulatory or clinical trial sources, and as of now, its molecular mechanism, developer, and clinical status are not established in leading databases or peer-reviewed literature. Therefore, the description primarily reflects pembrolizumab and indicates that **lanerkitug + pembrolizumab** represents an experimental or very early-stage investigational combination.